Evonik Industries AG

Evonik Industries AG leads the expanding global medical‑plastics market with high‑performance, FDA‑compliant polymers, blending R&D, supply‑chain resilience and strategic partnerships for healthcare innovation.

Evonik Industries AG shifts to high‑margin specialty chemicals, expanding U.S., Slovakian, Chinese and Shanghai facilities to boost profitability and reduce raw‑material risk.

Evonik names CFO Michael Rauch to tighten costs while launching AI‑powered Singapore pilot—boosting margins, cutting energy, and driving long‑term shareholder value.

Explore how Evonik Industries AG’s Q1 resilience, green‑chemistry innovation, and regulatory strategy shape investor outlook amid market uncertainty.

Evonik Industries sees a 33% share rise fueled by a temporary methionine price spike, but Berenberg’s updated €15 target highlights the short‑term nature of the upside, while a new “Tailor Made” cost‑cut program and upcoming Q1 earnings will test lo…

Evonik’s April 21 filing shows a major shareholder crossing a 10% voting threshold, while insider buying signals confidence—watch for future strategic shifts.

Evonik’s new CFO Michael Rauch and extended CEO term signal steadier leadership; analysts lift the rating, share price rises, yet the stock remains oversold—could be a value play?

Evonik Industries’ new CFO, price hikes, and dividend shift aim to boost margins and ROIC—discover how these moves shape the chemical firm’s future value.

Evonik Industries AG shows resilience amid volatile crude prices, thriving on specialty silica, green chemistry, and fine chemicals while boosting sustainable growth and pricing power.

Explore how Evonik Industries AG’s nanocatalysts, sodium cyanide expertise, and strategic cost‑optimisation boost profitability and sustainability in the evolving chemical sector.